REG - Diaceutics PLC - Board Changes

DiaceuticsAnnouncement

23/07/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240723:nRSW3687Xa&default-theme=true

RNS Number : 3687X  Diaceutics PLC  23 July 2024

Diaceutics PLC - Board Changes

 

Belfast and London, 23 July 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, today announces the following
changes to its board.

 

Deborah Davis has today informed the board after three and a half years'
service as Non-Executive Chair of Diaceutics, of her intention to step down
from the board effective 1 October 2024.

 

Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed
Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve
as a Non-Executive Director on the Remuneration and Audit & Risk
Committees.

 

Deborah Davis, Non-Executive Chair of Diaceutics commented: "With a mixture of
pride and gratitude, I announce my decision to step down as Chair of
Diaceutics. During my tenure, our collective efforts have scaled the Company
and transformed its business model, delivering significant growth and
positioning Diaceutics as a key commercialisation partner to pharma and
biotech companies in their quest to find patients that benefit from their
precision medicines. I extend my deepest gratitude to our board, executive
team, employees, partners, and shareholders for their unwavering support.
Under Peter's stewardship, I am confident the Company will continue to grow
and succeed."

 

Ryan Keeling, Chief Executive Officer of Diaceutics commented: "I would like
to thank Deborah for her tireless dedication and efforts in guiding Diaceutics
through a crucial stage in our development and growth as a public company. We
will miss her presence and wish her well for her current and future roles. I
look forward to working closely with the board and continuing my close
partnership with Peter in his new capacity as Chair."

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZGZNLZZGDZM